Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $294.0 million.

  • Dexcom's Cash from Operations fell 245.52% to $294.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 4559.88%. This contributed to the annual value of $1.4 billion for FY2025, which is 4559.88% up from last year.
  • Per Dexcom's latest filing, its Cash from Operations stood at $294.0 million for Q4 2025, which was down 245.52% from $659.9 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Cash from Operations registered a high of $659.9 million during Q3 2025, and its lowest value of $27.8 million during Q1 2021.
  • For the 5-year period, Dexcom's Cash from Operations averaged around $214.5 million, with its median value being $194.9 million (2023).
  • The largest annual percentage gain for Dexcom's Cash from Operations in the last 5 years was 136315.79% (2021), contrasted with its biggest fall of 6002.6% (2021).
  • Quarter analysis of 5 years shows Dexcom's Cash from Operations stood at $105.8 million in 2021, then increased by 25.24% to $132.5 million in 2022, then rose by 0.83% to $133.6 million in 2023, then skyrocketed by 125.6% to $301.4 million in 2024, then fell by 2.46% to $294.0 million in 2025.
  • Its Cash from Operations stands at $294.0 million for Q4 2025, versus $659.9 million for Q3 2025 and $303.0 million for Q2 2025.